Hormone therapy is associated with better body composition and adipokine/glucose profiles: A study with monozygotic co-twin control design

Menopause

Volumn 19, Issue 12, 2012, Pages 1329-1335

  Ahtiainen, Maarit ^a   Alen, Markku ^b   Pöllänen, Eija ^a   Pulkkinen, Suvi ^a   Ronkainen, Paula H A ^a   Kujala, Urho M ^a   Kaprio, Jaakko ^c,d   Sipilä, Sarianna ^a   Kovanen, Vuokko ^a  

^a UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Adipokines; Adipose tissue; Estrogen; Glucose metabolism; Menopause

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ESTRADIOL; ESTROGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LEPTIN; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGESTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TIBOLONE;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; HYPOGONADISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE; LIPID BLOOD LEVEL; MONOZYGOTIC TWINS; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; SKELETAL MUSCLE; WAIST HIP RATIO;

ADIPOKINES; ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; CASE-CONTROL STUDIES; CHEMOKINE CCL2; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; INSULIN RESISTANCE; LEUKOCYTES; LIPIDS; MIDDLE AGED; MUSCLE, SKELETAL; POSTMENOPAUSE; PREMENOPAUSE; RNA, MESSENGER; SEX HORMONE-BINDING GLOBULIN; TWINS, MONOZYGOTIC; WAIST-HIP RATIO;

EID: 84871241078     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31825a3344     Document Type: Article

References (63)

1. Ley CJ, Lees B, Stevenson JC. Sex-and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992;55:950-954.
2. Tchernof A, Desmeules A, Richard C, et al. Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab 2004;89:3425-3430.
3. Sites CK, Calles-Escandon J, Brochu M, Butterfield M, Ashikaga T, Poehlman ET. Relation of regional fat distribution to insulin sensitivity in postmenopausal women. Fertil Steril 2000;73:61-65.
4. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science 1997;278:419-424.
5. Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown) 2008;9:987-992.
6. Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008;4:215-222.
7. Guthrie JR, Dennerstein L, Taffe JR, et al. Central abdominal fat and endogenous hormones during the menopausal transition. Fertil Steril 2003;79:1335-1340.
8. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med 2008;168:1568-1575.
9. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) 2010;18: 604-610.
10. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol 2002;172:423-440.
11. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006;395:1-19.
12. Philippou A, Halapas A, Maridaki M, Koutsilieris M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 2007;7:208-218.
13. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro-and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999;515:287-291.
14. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
15. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-> induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005;54:2939-2945.
16. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 2009;117:95-109.
17. Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med 2006; 3:254-269.
18. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008;60:10-18.
19. Stramba-Badiale M. Postmenopausal hormone therapy and the risk of cardiovascular disease. J Cardiovasc Med (Hagerstown) 2009;10:303-309.
20. Toth MJ, Matthews DE, Tracy RP, Previs MJ. Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. Am J Physiol Endocrinol Metab 2005;288:E883-E891.
21. Stork S, von Schacky C, Angerer P. The effect of 17A-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002;165:301-307.
22. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
23. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
24. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
25. Ronkainen PH, Kovanen V, Alen M, et al. Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs. J Appl Physiol 2009;107:25-33.
26. Kaprio J, Sarna S, Koskenvuo M, Rantasalo I. The Finnish Twin Registry: formation and compilation, questionnaire study, zygosity determination procedures, and research program. Prog Clin Biol Res 1978; 24:179-184.
27. Pollanen E, Sipila S, Alen M, et al. Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre-and post-menopausal women. Aging Cell 2011;10:650-660.
28. Nelson RE, Grebe SK, OKane DJ, Singh RJ. Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 2004;50:373-384.
29. Ankarberg-Lindgren C, Norjavaara E. Twenty-four hours secretion pattern of serum estradiol in healthy prepubertal and pubertal boys as determined by a validated ultra-sensitive extraction RIA. BMC Endocr Disord 2008;8:10.
30. Turpeinen U, Linko S, Itkonen O, Hamalainen E. Determination of testosterone in serum by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest 2008;68:50-57.
31. Bjornerem A, Straume B, Midtby M, et al. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso Study. J Clin Endocrinol Metab 2004;89: 6039-6047.
32. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endo-crinol Metab 1999;84:3666-3672.
33. Milewicz A, Tworowska U, Demissie M. Menopausal obesityVmyth or fact? Climacteric 2001;4:273-283.
34. Ferrannini E, Balkau B, Coppack SW, et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007;92:2885-2892.
35. Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The heritability of body mass index among an international sample of monozygotic twins reared apart. Int J Obes Relat Metab Disord 1996;20: 501-506.
36. Pietilainen KH, Rissanen A, Laamanen M, et al. Growth patterns in young adult monozygotic twin pairs discordant and concordant for obesity. Twin Res 2004;7:421-429.
37. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983;72:1150-1162.
38. Bouchard C, Despres JP, Mauriege P. Genetic and nongenetic determinants of regional fat distribution. Endocr Rev 1993;14:72-93.
39. Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 2009;94:1104-1110.
40. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005;111:1242-1249.
41. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-2838.
42. Maggio M, Lauretani F, Basaria S, et al. Sex hormone binding globulin levels across the adult lifespan in womenVthe role of body mass index and fasting insulin. J Endocrinol Invest 2008;31:597-601.
43. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
44. Pietilainen KH, Rog T, Seppanen-Laakso T, et al. Association of lip-idome remodeling in the adipocyte membrane with acquired obesity in humans. PLoS Biol 2011;9:e1000623.
45. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adi-ponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14: 561-566.
46. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-981.
47. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302:179-188.
48. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
49. Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005;54:2003-2011.
50. Huber J, Kiefer FW, Zeyda M, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 2008;93:3215-3221.
51. Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 2010;18:884-889.
52. Sieminska L, Wojciechowska C, Niedziolka D, et al. Effect of post-menopause and hormone replacement therapy on serum adiponectin levels. Metabolism 2005;54:1610-1614.
53. Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 2007;196:123.e1-123.e7.
54. Im JA, Lee JW, Lee HR, Lee DC. Plasma adiponectin levels in post-menopausal women with or without long-term hormone therapy. Maturitas 2006;54:65-71.
55. Ahtiainen M, Pollanen E, Ronkainen PH, et al. Age and estrogen-based hormone therapy affect systemic and local IL-6 and IGF-1 pathways in women [e-pub]. Age (Dordr) 2011.
56. Page ST, Herbst KL, Amory JK, et al. Testosterone administration suppresses adiponectin levels in men. J Androl 2005;26:85-92.
57. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004;60:500-507.
58. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156:595-602.
59. Mohlig M, Wegewitz U, Osterhoff M, et al. Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002;34:655-658.
60. Brame LA, Considine RV, Yamauchi M, Baron AD, Mather KJ. Insulin and endothelin in the acute regulation of adiponectin in vivo in humans. Obes Res 2005;13:582-588.
61. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006;147:2458-2467.
62. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-554.
63. Faulds MH, Zhao C, Dahlman-Wright K, Gustafsson JA. The diversity of sex steroid action: regulation of metabolism by estrogen signaling. J Endocrinol 2012;212:3-12.